Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer - Trial NCT06310369
Access comprehensive clinical trial information for NCT06310369 through Pure Global AI's free database. This Phase 2 trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC and is currently Not yet recruiting. The study focuses on Bladder Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
European Organisation for Research and Treatment of Cancer - EORTC
Timeline & Enrollment
Phase 2
Mar 01, 2025
Mar 01, 2030
Primary Outcome
Proportion of patients with a CR at 6 months post-radiotherapy
Summary
We aim to investigate a possible role for radiotherapy in good prognosis bladder cancer
 patients has been identified as a possible alternative to cystectomy, especially for patients
 non-eligible for surgery but has yet to be fully explored.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06310369
Non-Device Trial